Financial News Feed

Stronger Sell Today AIMT ranks #4689 as SELL CANDIDATE. Weaker Sell
Today AIMT ranks #4689 as SELL CANDIDATE.

AIMT stock Aimmune Therapeutics

AIMT stock
Aimmune Therapeutics

Taking a look at the current quarter EPS consensus estimate for Aimmune Therapeutics, Inc. (NASDAQ:AIMT), we can see that the number is standing at -0.88. This estimate is comprised of 8 contributing ...

Read more

<!-- .bwalignc {text-align: center} --> Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced th...

Read more

Research Analysts’ downgrades for Thursday, January 17th: AGNC Investment (NASDAQ:AGNC) was downgraded by analysts at BidaskClub from a buy rating to a hold rating. Aimmune Therapeutics (NASDAQ:AIMT...

Read more

Proven Pharmaceutical Leader Brings Deep, Global Experience with Successful Product Launches, Commercialization and Strategic Planning...

Read more

The recent price of 23.47 for shares of Aimmune Therap (AIMT) has put the price level below the Balance Step, indicating a near-term bearish pattern developing. Calculated from the last five balance p...

Read more

Even though short-term trading can be very profitable, it can also be a huge risk. Short-term lasts from anywhere from a few minutes or several days or weeks. Traders have to truly understand the risk...

Read more

The Price to book ratio is the current share price of a company divided by the book value per share. The Price to Book ratio for Fevertree Drinks Plc AIM:FEVR is 19.211079. A lower price to book ratio...

Read more

The twenty one day Wilder Moving Average has recently been seen below the fifty day Simple Moving Average on shares of Aimmune Therap (AIMT). Traders following these numbers may be watching for a poss...

Read more

Aimmune Therapeutics has confirmed that the government shutdown will delay the FDA’s review of AR101, its oral immunotherapy for peanut allergy....

Read more

(RTTNews) - Today's Daily Dose brings you news about the approval of the world's first device for treatment of premature babies and newborns with an opening in their hearts; the impact of the U.S. gov...

Read more

Aimmune Therapeutics Inc. (AIMT) had a rough trading day for Monday January 14 as shares tumbled 5.19%, or a loss of $-1.33 per share, to close at $24.30. After opening the day at $25.47, shares...

Read more

As many veteran investors have already seen, market movements are extremely hard to accurately predict. Financial news outlets are always producing headlines and offering predictions for future market...

Read more

Empire State Realty Trust, Inc. (NYSE:ESRT) has a current MF Rank of 8970. Developed by hedge fund manager Joel Greenblatt, the intention of the formula is to spot high quality companies that are trad...

Read more

Aimmune Therap (AIMT) shares are seeing solid buying inflow as the Chaikin Money Index is holding above zero. If the price consistently closes in the upper half of the daily range on high volume the i...

Read more

Stocks in Review: Aimmune Therap (AIMT)
02:22am, Saturday, 12'th Jan 2019
Investors may be watching the technical signals on shares of Aimmune Therap (AIMT). Looking at the 50-day moving average vs price signal, the reading is measured at Buy. This indicator is used to watc...

Read more

News Feed powered by

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank